Cystic fibrosis lung disease: Interplay of a microbial microcosm and extremes of inflammation

Israel Medical Association Journal

Volumn 8, Issue 1, 2006, Pages 58-59

  Blau, Hannah ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

CFTR protein; Cystic fibrosis; Inflammation; Microbiology

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DORNASE ALFA; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SIGNAL PEPTIDE; STEROID; TRANSMEMBRANE CONDUCTANCE REGULATOR;

BURKHOLDERIA CEPACIA; CHRONIC INFLAMMATION; CLINICAL TRIAL; CROSS INFECTION; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG TARGETING; EDITORIAL; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LONG TERM CARE; LUNG FIBROSIS; LUNG FUNCTION; LUNG LAVAGE; MICROCOSM; MORTALITY; NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SURVIVAL RATE; UPREGULATION;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; INFLAMMATION;

EID: 30944461839     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (20)

1. Katznelson D. On the complexity of the pulmonary microbiology in cystic fibrosis. Thoughts of a clinician. IMAJ 2006;8:49-52.
2. Soferman R. Immunopathophysiologic mechanisms of cystic fibrosis. IMAJ 2006;8:44-48.
3. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681-9.
4. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Cystic Fibrosis Foundation Consensus on Infection Control Participants. Am J Infect Control 2003;(3 Suppl):S1-2.
5. Ramsey BW. To cohort or not to cohort - how transmissible is Pseudomonas aeruginosa? [Editorial]. Am J Respir Crit Care Med 2002;166:906-7.
6. LiPuma JJ. Preventing Burkholderia cepacia complex infection in cystic fibrosis: is there a middle ground? J Pediatr 2002;141:467-9.
7. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004;42(11):5176-83.
8. Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomized, double-blind, controlled clinical trial. Lancet 2005;366:463-71.
9. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
10. Al-Aloul M, Crawley J, Winstanley C, et al. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 2004;59:334-6.
11. Cantin A. Cystic fibrosis lung inflammation: early, sustained and severe. Am J Respir Crit Care Med 1995;151:939-41.
12. Eigen H, Rosenstein BJ, Fitzimmons S, Schidlow DV. Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate day prednisolone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-23.
13. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-54.
14. Armstrong DS, Hook SM, Jamsen KM, et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 2005;40:500-10.
15. Li J, Johnson XD, Iazvovskaia S, Tan A, Lin A, Hershenson MB. Signaling intermediates required for NFkB activation and IL-8 expression in CF bronchial epithelial cells. Am J Physiol 2003;284:L307-15.
16. Weber AJ, Soong G, Bryan R, Saba S, Prince A. Activation of NFkappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function. Am J Physiol 2001;281:L71-8.
17. Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. Translational review. Am J Respir Cell Mol Biol 2004;31:377-81.
18. Drumm ML, Konstan MW, Schluchter MD, et al. Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005;353:1443-53.
19. Saiman L, Marshal BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.
20. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-25.